Evaluating the importance of HER2 biomarker performance in diagnosing and relating it to other clinical factors in women with breast cancer referring to the Besat Clinic

Abstract

Introduction: Breast cancer is one of the most common cancers in women and the second leading cause of death from cancer in women aged 20-59. Correspondingly, tumor markers such as HER-2/neu and PR ER P53 can be used to determine the severity of the disease and how to treat these patients. The purpose of this study was to investigate the importance of HER-2 biomarker function in diagnosis and its relationship with other clinical factors in women with breast cancer. Materials and Methods: This cross-sectional-analytical study included all breast cancer patients who were referred to Rasht's Besat Clinic between 2018 and 2019, and their breast cancer was confirmed by pathology results. The CVR coefficient was obtained for each question (-0.8 to 1) and the CVI index was above 80%. HER-2 biomarker status was recorded in immunohistochemical evaluation. Results: In this study, there is also a significant relationship between HER-2 biomarkers with the age of diagnosis, place of residence, marital status, education, exercise frequency, menstrual cycle, age at first menstruation, age at first live birth, history of abortion, history of Breastfeeding, history of the contraceptive hormone, history of smoking, alcohol, drugs, history of breast cancer and non-breast cancer in first and second degree relatives, history of HPV, history of metastasis was not found. A significant correlation was found between HER-2 biomarker and weight, age of first pregnancy, and the number of children. Conclusion: Based on the results of this study, the expression of HER-2 biomarkers in breast cancer patients increases with increasing weight, increasing the age of patients, and decreasing the number of children.